Oragenics Past Earnings Performance
Past criteria checks 0/6
Oragenics's earnings have been declining at an average annual rate of -12.2%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 90.6% per year.
Key information
-12.2%
Earnings growth rate
47.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 90.6% |
| Return on equity | -109.8% |
| Net Margin | -10,864.0% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Oragenics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -14 | 4 | 10 |
| 30 Sep 22 | 0 | -14 | 5 | 0 |
| 30 Jun 22 | 0 | -15 | 4 | 0 |
| 31 Mar 22 | 0 | -17 | 5 | 0 |
| 31 Dec 21 | 0 | -16 | 5 | 0 |
| 30 Sep 21 | 0 | -18 | 5 | -19 |
| 30 Jun 21 | 0 | -18 | 6 | -15 |
| 31 Mar 21 | 0 | -26 | 5 | -4 |
| 31 Dec 20 | 0 | -26 | 5 | 0 |
| 30 Sep 20 | 0 | -26 | 4 | 22 |
| 30 Jun 20 | 0 | -25 | 4 | 21 |
| 31 Mar 20 | 0 | -17 | 4 | 13 |
| 31 Dec 19 | 0 | -16 | 4 | 12 |
| 30 Sep 19 | 0 | -15 | 4 | 11 |
| 30 Jun 19 | 0 | -15 | 4 | 10 |
| 31 Mar 19 | 0 | -13 | 4 | 7 |
| 31 Dec 18 | 0 | -11 | 4 | 6 |
| 30 Sep 18 | 0 | -10 | 4 | 5 |
| 30 Jun 18 | 0 | -8 | 3 | 4 |
| 31 Mar 18 | 0 | -7 | 3 | 4 |
| 31 Dec 17 | 0 | -7 | 3 | 4 |
| 30 Sep 17 | 0 | -8 | 4 | 5 |
| 30 Jun 17 | 0 | -8 | 4 | 4 |
| 31 Mar 17 | 0 | -8 | 4 | 5 |
| 31 Dec 16 | 0 | -8 | 4 | 5 |
| 30 Sep 16 | 0 | -8 | 4 | 4 |
Quality Earnings: UAV is currently unprofitable.
Growing Profit Margin: UAV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UAV is unprofitable, and losses have increased over the past 5 years at a rate of 12.2% per year.
Accelerating Growth: Unable to compare UAV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UAV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: UAV has a negative Return on Equity (-109.83%), as it is currently unprofitable.